MAIA Biotechnology Announces $736,600 Private Placement
MAIA Biotechnology (NYSE American: MAIA) announced a private placement to accredited investors for 603,769 shares of common stock at $1.22 per share, each accompanied by a warrant to buy one share at an exercise price of $1.52. The warrants become exercisable six months after issuance and expire three years from issuance.
The offering is expected to close on or about October 15, 2025, with gross proceeds of approximately $736,600 before offering expenses. The company intends to use net proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered in a private placement and are unregistered.
MAIA Biotechnology (NYSE American: MAIA) ha annunciato una collocazione privata a investitori accreditati per 603.769 azioni ordinarie a $1,22 per azione, ognuna accompagnata da un warrant per acquistare un’azione a un prezzo di esercizio di $1,52. I warrant diventano esercitabili sei mesi dalla data di emissione e scadono tre anni dalla data di emissione.
Si prevede che l’offerta si chiuda indicativamente il 15 ottobre 2025, con proventi lordi di circa $736.600 prima delle spese di offerta. La società intende utilizzare i proventi netti per finanziare la Fase 1 della Parte C della sperimentazione di Fase II THIO-101 e per il capitale circolante. I titoli sono offerti tramite una collocazione privata e non sono registrati.
MAIA Biotechnology (NYSE American: MAIA) anunció una colocación privada a inversores acreditados para 603.769 acciones ordinarias a $1.22 por acción, cada una acompañada de un warrant para comprar una acción a un precio de ejercicio de $1.52. Los warrants se volverán exercibles seis meses después de la emisión y expiran tres años desde la emisión.
La oferta se espera que cierre alrededor del 15 de octubre de 2025, con ingresos brutos de aproximadamente $736,600 antes de gastos de oferta. La empresa tiene la intención de utilizar los ingresos netos para financiar la Etapa 1 de la Parte C del ensayo THIO-101 de Fase II y para el capital de trabajo. Los valores se ofrecen en una colocación privada y no están registrados.
MAIA 생명공학(NYSE American: MAIA)은 인정된 투자자들에게 603,769 주의 보통주를 주당 $1.22에, 각 주당 하나의 주식 매수권이 동봉되어 $1.52의 행사 가격으로 매수할 수 있는 비공개 배정에 대해 발표했습니다. 매수권은 발행일로부터 6개월 후 행사 가능하며 발행일로부터 3년 후 만료됩니다.
공모는 대략 2025년 10월 15일경 종료될 것으로 예상되며, 공모 비용 전의 총수익은 약 $736,600입니다. 회사는 순수익을 2상 THIO-101 임상 2상 Part C의 1단계 자금 조달 및 운전자본으로 사용할 예정입니다. 증권은 비공개 배정으로 제공되며 등록되지 않았습니다.
MAIA Biotechnology (NYSE American: MAIA) a annoncé une placement privé auprès d’investisseurs accrédités pour 603 769 actions ordinaires à $1,22 par action, chacune accompagnée d’un warrant permettant d’acheter une action à un prix d’exercice de $1,52. Les warrants deviennent exerçables six mois après l’émission et expirent trois ans après l’émission.
L’offre devrait être clôturée vers le 15 octobre 2025, avec des produits bruts d’environ $736 600 avant les frais d’offre. La société a l’intention d’utiliser le produit net pour financer l’étape 1 de la Partie C de l’essai THIO-101 de la Phase II et pour le fonds de roulement. Les titres sont offerts dans le cadre d’un placement privé et ne sont pas enregistrés.
MAIA Biotechnology (NYSE American: MAIA) kündigte eine Privatplatzierung für akkreditierte Investoren über 603.769 Stammaktien zu $1,22 pro Aktie an, wobei jede Aktie mit einem Warrants zum Kauf einer Aktie zu einem Ausübungspreis von $1,52 begleitet wird. Die Warrants werden sechs Monate nach der Emission ausübbar sein und laufen drei Jahre nach der Emission ab.
Die Emission wird voraussichtlich um den 15. Oktober 2025 herum abgeschlossen sein, mit Bruttoerlösen von ca. $736.600 vor Emissionskosten. Das Unternehmen beabsichtigt, die Nettoeinnahmen zu verwenden, um Schritt 1 von Teil C der Phase-II-THIO-101-Studie zu finanzieren und für Working Capital. Die Wertpapiere werden in einer Privatplatzierung angeboten und sind nicht registriert.
MAIA Biotechnology (NYSE American: MAIA) أعلنت عن طرح خاص للمستثمرين المعتمدين لعدد 603,769 سهماً عادياً بسعر $1.22 للسهم، وكل واحد مرفق بمشتري حق شراء سهم واحد عند سعر تنفيذ قدره $1.52. تصبح مشتريات الأسهم قابلة للتنفيذ بعد ستة أشهر من الإصدار وتنتهي صلاحيتها بعد ثلاثة أعوام من تاريخ الإصدار.
من المتوقع أن يغلق العرض في 15 أكتوبر 2025 تقريباً، بإيرادات إجمالية قدرها نحو $736,600 قبل مصاريف العرض. تنوي الشركة استخدام العائدات الصافية لتمويل الخطوة 1 من الجزء C من تجربة THIO-101 في المرحلة الثانية وللرأسمال العامل. وتُطرح الأوراق المالية في طرح خاص وليست مُسجلة.
MAIA Biotechnology (NYSE American: MAIA) 宣布面向合格投资者进行私募配售，发行603,769股普通股，每股价格为$1.22，每股附带一张权证，行使价为$1.52，权证自发行后六个月起可行使，自发行之日起三年后到期。
本次发行预计在2025年10月15日左右完成，总募资约为$736,600，在发行费用之前。公司拟将净募集资金用于资助THIO-101 II 期试验的C部第1步以及用于运营资金。证券以私募方式发行，尚未注册。
- Gross proceeds of $736,600 expected
- Proceeds designated to fund Step 1, Part C of Phase II THIO-101
- Warrants provide potential additional capital when exercised
- Warrants exercisable six months after issuance
- 603,769 shares issued, causing immediate dilution
- Accompanying warrants create further potential dilution
- Securities are unregistered, restricting resale
- Gross proceeds reduced by offering expenses
Insights
Small private placement raises
MAIA Biotechnology sold 603,769 common shares at
The net proceeds will fund execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital. Warrants begin exercise six months after issuance and expire three years after issuance, which limits immediate dilution but extends potential dilution over a multi-year window.
Key dependencies and near-term items to watch include the closing on or about
CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 603,769 shares of common stock at a purchase price of
The gross proceeds from the offering are expected to be approximately
The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) completion of the private placement, (ii) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (iii) our ability to advance product candidates into, and successfully complete, clinical studies, (iv) the timing or likelihood of regulatory filings and approvals, (v) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (vi) the rate and degree of market acceptance of our product candidates, (vii) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (viii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
FAQ
What did MAIA (MAIA) announce on October 13, 2025 regarding a private placement?
How much money will MAIA raise in the private placement and what are the proceeds for?
When can investors exercise the MAIA warrants issued in the October 2025 private placement?
Will the MAIA private placement shares and warrants be registered for resale?
How will the private placement affect MAIA shareholders immediately?
